Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
InChI
InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:52:37 UTC 2023
by
admin
on
Fri Dec 15 15:52:37 UTC 2023
|
Record UNII |
5QZO15J2Z8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA03
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
NDF-RT |
N0000175784
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
WHO-VATC |
QA02BA03
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
WHO-ATC |
A02BA53
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
LIVERTOX |
NBK548228
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
WHO-VATC |
QA02BA53
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
||
|
NDF-RT |
N0000000151
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Famotidine
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
DTXSID5023039
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
DB00927
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
757810
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
D015738
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
SUB07503MIG
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
5217
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
100000092363
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
7074
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
3325
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
m5241
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL902
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
4278
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | RxNorm | ||
|
FAMOTIDINE
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
1269200
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
4975
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
1129
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
W-33
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
3572
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
C29045
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY | |||
|
76824-35-6
Created by
admin on Fri Dec 15 15:52:37 UTC 2023 , Edited by admin on Fri Dec 15 15:52:37 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
Following IV administration
URINE
|
||
|
TARGET->INVERSE AGONIST |
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->INVERSE AGONIST |
|
||
|
TRANSPORTER -> NON-INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||